Cargando…
Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease
OBJECTIVE: Evidence shows that the impairment of executive function (EF) is mainly attributed to the degeneration of frontal-striatal dopamine pathway. Glial cell line-derived neurotrophic factor (GDNF), as the strongest protective neurotrophic factor for dopaminergic neurons (DANs), may play a role...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995904/ https://www.ncbi.nlm.nih.gov/pubmed/36908789 http://dx.doi.org/10.3389/fnins.2023.1136499 |
_version_ | 1784902923435638784 |
---|---|
author | Tong, Shu-Yan Wang, Rui-Wen Li, Qian Liu, Yi Yao, Xiao-Yan Geng, De-Qin Gao, Dian-Shuai Ren, Chao |
author_facet | Tong, Shu-Yan Wang, Rui-Wen Li, Qian Liu, Yi Yao, Xiao-Yan Geng, De-Qin Gao, Dian-Shuai Ren, Chao |
author_sort | Tong, Shu-Yan |
collection | PubMed |
description | OBJECTIVE: Evidence shows that the impairment of executive function (EF) is mainly attributed to the degeneration of frontal-striatal dopamine pathway. Glial cell line-derived neurotrophic factor (GDNF), as the strongest protective neurotrophic factor for dopaminergic neurons (DANs), may play a role in EF to some extent. This study mainly explored the correlation between serum GDNF concentration and EF performance in Parkinson’s disease (PD). METHODS: This study recruited 45 healthy volunteers (health control, HC) and 105 PD patients, including 44 with mild cognitive impairment (PD-MCI), 20 with dementia (PD-D), and 20 with normal cognitive function (PD-N). Neuropsychological tests were performed to evaluate EF (working memory, inhibitory control, and cognitive flexibility), attention, language, memory, and visuospatial function. All subjects were tested for serum GDNF and homovanillic acid (HVA) levels by ELISA and LC-ESI-MS/MS, respectively. RESULTS: PD-MCI patients showed impairments in the trail making test (TMT) A (TMT-A), TMT-B, clock drawing test (CDT) and semantic fluency test (SFT), whereas PD-D patients performed worse in most EF tests. With the deterioration of cognitive function, the concentration of serum GDNF and HVA in PD patients decreased. In the PD group, the serum GDNF and HVA levels were negatively correlated with TMT-A (r(GDNF) = −0.304, P < 0.01; r(HVA) = −0.334, P < 0.01) and TMT-B (r(GDNF) = −0.329, P < 0.01; r(HVA) = −0.323, P < 0.01) scores. Serum GDNF levels were positively correlated with auditory verbal learning test (AVLT-H) (r = 0.252, P < 0.05) and SFT (r = 0.275, P < 0.05) scores. Serum HVA levels showed a positively correlation with digit span test (DST) (r = 0.277, P < 0.01) scores. Stepwise linear regression analysis suggested that serum GDNF and HVA concentrations and UPDRS-III were the influence factors of TMT-A and TMT-B performances in PD patients. CONCLUSION: The decrease of serum GDNF concentration in PD patients was associated with impaired inhibitory control, cognitive flexibility, and attention performances. The changes of GDNF and HVA might synergistically participate in the occurrence and development of executive dysfunction in PD patients. |
format | Online Article Text |
id | pubmed-9995904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99959042023-03-10 Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease Tong, Shu-Yan Wang, Rui-Wen Li, Qian Liu, Yi Yao, Xiao-Yan Geng, De-Qin Gao, Dian-Shuai Ren, Chao Front Neurosci Neuroscience OBJECTIVE: Evidence shows that the impairment of executive function (EF) is mainly attributed to the degeneration of frontal-striatal dopamine pathway. Glial cell line-derived neurotrophic factor (GDNF), as the strongest protective neurotrophic factor for dopaminergic neurons (DANs), may play a role in EF to some extent. This study mainly explored the correlation between serum GDNF concentration and EF performance in Parkinson’s disease (PD). METHODS: This study recruited 45 healthy volunteers (health control, HC) and 105 PD patients, including 44 with mild cognitive impairment (PD-MCI), 20 with dementia (PD-D), and 20 with normal cognitive function (PD-N). Neuropsychological tests were performed to evaluate EF (working memory, inhibitory control, and cognitive flexibility), attention, language, memory, and visuospatial function. All subjects were tested for serum GDNF and homovanillic acid (HVA) levels by ELISA and LC-ESI-MS/MS, respectively. RESULTS: PD-MCI patients showed impairments in the trail making test (TMT) A (TMT-A), TMT-B, clock drawing test (CDT) and semantic fluency test (SFT), whereas PD-D patients performed worse in most EF tests. With the deterioration of cognitive function, the concentration of serum GDNF and HVA in PD patients decreased. In the PD group, the serum GDNF and HVA levels were negatively correlated with TMT-A (r(GDNF) = −0.304, P < 0.01; r(HVA) = −0.334, P < 0.01) and TMT-B (r(GDNF) = −0.329, P < 0.01; r(HVA) = −0.323, P < 0.01) scores. Serum GDNF levels were positively correlated with auditory verbal learning test (AVLT-H) (r = 0.252, P < 0.05) and SFT (r = 0.275, P < 0.05) scores. Serum HVA levels showed a positively correlation with digit span test (DST) (r = 0.277, P < 0.01) scores. Stepwise linear regression analysis suggested that serum GDNF and HVA concentrations and UPDRS-III were the influence factors of TMT-A and TMT-B performances in PD patients. CONCLUSION: The decrease of serum GDNF concentration in PD patients was associated with impaired inhibitory control, cognitive flexibility, and attention performances. The changes of GDNF and HVA might synergistically participate in the occurrence and development of executive dysfunction in PD patients. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995904/ /pubmed/36908789 http://dx.doi.org/10.3389/fnins.2023.1136499 Text en Copyright © 2023 Tong, Wang, Li, Liu, Yao, Geng, Gao and Ren. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Tong, Shu-Yan Wang, Rui-Wen Li, Qian Liu, Yi Yao, Xiao-Yan Geng, De-Qin Gao, Dian-Shuai Ren, Chao Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease |
title | Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease |
title_full | Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease |
title_fullStr | Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease |
title_full_unstemmed | Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease |
title_short | Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson’s disease |
title_sort | serum glial cell line-derived neurotrophic factor (gdnf) a potential biomarker of executive function in parkinson’s disease |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995904/ https://www.ncbi.nlm.nih.gov/pubmed/36908789 http://dx.doi.org/10.3389/fnins.2023.1136499 |
work_keys_str_mv | AT tongshuyan serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT wangruiwen serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT liqian serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT liuyi serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT yaoxiaoyan serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT gengdeqin serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT gaodianshuai serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease AT renchao serumglialcelllinederivedneurotrophicfactorgdnfapotentialbiomarkerofexecutivefunctioninparkinsonsdisease |